Applied Genetic Technologies (AGTC) PT Set at $8.00 by HC Wainwright

Applied Genetic Technologies (NASDAQ:AGTC) has been given a $8.00 target price by equities researchers at HC Wainwright in a report issued on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 105.13% from the company’s current price.

AGTC has been the topic of a number of other research reports. Zacks Investment Research lowered Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. ValuEngine lowered Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, January 17th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $9.00 target price on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $10.17.

Applied Genetic Technologies (NASDAQ AGTC) traded down $0.35 during mid-day trading on Friday, hitting $3.90. The stock had a trading volume of 102,103 shares, compared to its average volume of 116,407. The firm has a market capitalization of $76.90, a PE ratio of -15.38 and a beta of 2.03. Applied Genetic Technologies has a 52 week low of $3.25 and a 52 week high of $8.40.

Applied Genetic Technologies (NASDAQ:AGTC) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. equities analysts predict that Applied Genetic Technologies will post -1.14 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of AGTC. Dimensional Fund Advisors LP lifted its position in shares of Applied Genetic Technologies by 66.6% during the second quarter. Dimensional Fund Advisors LP now owns 266,441 shares of the biotechnology company’s stock worth $1,359,000 after acquiring an additional 106,558 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Applied Genetic Technologies by 1,080.3% in the second quarter. Goldman Sachs Group Inc. now owns 143,606 shares of the biotechnology company’s stock valued at $732,000 after acquiring an additional 131,439 shares during the last quarter. Nine Chapters Capital Management LLC bought a new position in Applied Genetic Technologies in the third quarter valued at $113,000. Citadel Advisors LLC increased its stake in Applied Genetic Technologies by 304.6% in the third quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock valued at $163,000 after acquiring an additional 31,070 shares during the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in Applied Genetic Technologies in the second quarter valued at $178,000. 46.59% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/09/applied-genetic-technologies-agtc-pt-set-at-8-00-by-hc-wainwright.html.

Applied Genetic Technologies Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply